N-{[1-(4-methoxyphenyl)cyclohexyl]methyl}-1-pyrimidyn-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide | 1104271-01-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-{[1-(4-methoxyphenyl)cyclohexyl]methyl}-1-pyrimidyn-2-yl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide
• 英文别名: N-[[1-(4-methoxyphenyl)cyclohexyl]methyl]-1-pyrimidin-2-yl-3-(trifluoromethyl)pyrazole-4-carboxamide
• CAS: 1104271-01-3
• 化学式: C₂₃H₂₄F₃N₅O₂
• 分子量: 459.471
• InChiKey: JPQOKWIFPNXXIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• 5-Membered Heterocyclic Amides And Related Compounds
  申请人：H. Lundbeck A/S

  公开号：US20150005293A1

  公开（公告）日：2015-01-01

  5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了公式为5-成员杂环酰胺及相关化合物：其中变量如此处所述。这些化合物是配体，可用于体内或体外调节特定受体活性，特别适用于治疗与人类、家养伴侣动物和家畜动物的病理性受体激活有关的疾病。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的该类配体的方法。
• 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS
  申请人：Lundbeck, H., A/S

  公开号：EP2178865B1

  公开（公告）日：2015-08-19
• US9133204B2
  申请人：——

  公开号：US9133204B2

  公开（公告）日：2015-09-15
• [EN] 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS<br/>[FR] AMIDES HETEROCYCLIQUES A 5 CHAINONS ET COMPOSES ASSOCIES
  申请人：NEUROGEN CORP

  公开号：WO2009012482A2

  公开（公告）日：2009-01-22

  5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.